Latest news

March 2024 International Master in Sustainable Drug Discovery (S-DISCO) received ACS-CES award. link

15th Dec 2023 Vasilis Fougiaxis received second prize for best oral presentation and Florian Descamps second prize for best poster during the drug discovery day.

Learn more

Therapeutic Innovation : Discovery Across Boundaries

U1177 (formerly U761), directed by Pr. Benoit Deprez, is dedicated to drug design, discovery and selection.

The Lab's mission is to design and study compounds that modulates selected molecular targets in a desired way to treat infectious and metabolic diseases.

Our projects engage researchers across physical, chemical and biological sciences to trade ideas and knowledge and sincerely endeavor to validate new therapeutic concepts with drug prototypes and bring drugs candidates to the clinic.

  • Developing cutting edge methods for quantitative pharmacology (High Content Screening, Pharmacokinetics)
  • Designing the next generation of anti-TB antibiotics : ethionamide boosters.
  • Deciphering the role(s) of Insulin Degrading Enzyme in diabetes with several families of modulators.
  • Modulating the molecular interplay between intestine, liver and muscles with TGR5 ligands to treat diabetes.
  • Developing small chemical modulators of antigenic presentation.

We are open to any type of collaboration with biologists or chemist from academia and industry where medicinal chemistry, in vitro pharmacology and pharmacokinetics enable or accelerate the translation of new therapeutic concept into drug discovery.

Our researchers are committed to the highest standards of scientific quality and integrity in everything they do. We use up-to date electronic lab books to sustainably capitalize knowledge and facilitate collaborations between multiple research sites.

Most of our researchers are also faculty members who teach in PharmD and MSc courses in pharmacy, drug discovery, medicinal chemistry, organic chemistry, and R&D strategies.

A journey with the team

Member of networks Chembioscreen and Chembiofrance

Latest Publications

(truncated titles)

Andres, M., et al. Insulin-degrading enzyme inhibition increases the unfolded protein response and favours lipid accumulation in the liver. Br. J. Pharmacol.,2024. link.

Mosheim, J. R, et al. Biocatalytic Regioselective O-acylation of Sesquiterpene Lactones from Chicory: A Pathway to Novel Ester Derivatives. Chembiochem,2024. link.

Brier, L., et al. Capillary electrokinetic chromatography for chiral separation of potential SARS-CoV-2 3CL protease inhibitors. Electrophoresis,2024. link.

Jiménez-Castellanos, J.-C., et al. Characterization of pyridylpiperazine-based efflux pump inhibitors for Acinetobacter baumannii. JAC-AMR,2023. link.

Vieira Da Cruz, A., et al. Pyridylpiperazine efflux pump inhibitor boosts in vivo antibiotic efficacy against K. pneumoniae. EMBO Mol. Med.,2023. link.

Gioia, B., et al. Regioselective and Stereoselective Synthesis of Parthenolide Analogs. Int. J. Mol. Sci.,2023. link.

LabLife in 10 languages

Discover 11 young researchers who speak without filter in their mother tongue!

Follow link